Clinical Trial

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-07; most recent amendment 2026-01-14.
Status change: Not Yet Recruiting → Recruiting 2025-11-11
Trial Details
NCT Number NCT06973564
Lead Sponsor Jacobio Pharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 294 participants
Start Date 2025-05-29
Primary Completion 2027-11 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-16